Karen S. Stevens
Social Work at Pearl St, Westminster, CO
License number
Colorado 992783
Issued Date
Dec 31, 2001
Renew Date
Sep 1, 2011
Expiration Date
Feb 4, 2013
Type
Licensed Clinical Social Worker
Address
Address
9101 Pearl St, Westminster, CO 80229
Personal information
See more information about Karen S. Stevens at radaris.comName
Address
Phone
46913 County Road 89, Byers, CO 80103
4471 Mohawk Dr, Larkspur, CO 80118
4543 Castle Cir, Broomfield, CO 80023
7575 E Colfax Ave, Denver, CO 80220
6605 E Columbine Dr, U S A F Academy, CO 80840
Professional information
Central Administration Of Stable Formulations Of Therapeutic Agents For Cns Conditions
US Patent:
2012007, Mar 22, 2012
Filed:
Mar 18, 2011
Appl. No.:
13/051950
Inventors:
Daniel J. Abrams - Denver CO, US
Raymond Bunch - Phoenix AZ, US
Tom Anchordoquy - Lakewood CO, US
Karen Elizabeth Stevens - Westminster CO, US
Raymond Bunch - Phoenix AZ, US
Tom Anchordoquy - Lakewood CO, US
Karen Elizabeth Stevens - Westminster CO, US
Assignee:
The Regents of the University of Colorado - Denver CO
International Classification:
A61K 31/7076, A61K 31/53, A61K 31/196, A61K 31/55, A61K 31/19, A61K 31/551, A61K 31/4178, A61K 31/15, A61K 31/138, A61K 31/135, A61P 25/08, A61P 25/00, A61P 25/18, A61P 25/28, A61P 25/24, A61P 25/20, A61P 25/22, A61K 31/27
US Classification:
514 46, 514483, 514242, 514562, 514217, 514557, 514220, 514397, 514664, 514651, 514647, 514656
Abstract:
The present invention concerns compositions, methods and/or apparatus of central administration of various CNS-ac-Live agents. In particular embodiments, intrathecal administration is advantageous for decreasing the systemic concentrations of CNS agent, thereby decreasing side effect toxicity, while allowing more effective delivery of the agent to the site of action, simultaneously decreasing the dosage delivered to the subject. In particular embodiments, ICV delivery may be of use for patients who have previously proven to be refractory to systemic administration of CNS agents, in some cases due to systemic side effects, or for those patients whose symptoms are of sufficient severity to warrant more aggressive therapeutic intervention. ICV administration allows not only lower systemic concentration but also higher therapeutically effective concentration within the CNS.
Central Administration Of Stable Formulations Of Therapeutic Agents For Cns Conditions
US Patent:
2009020, Aug 20, 2009
Filed:
Jan 17, 2007
Appl. No.:
12/161149
Inventors:
Daniel J. Abrams - Denver CO, US
Raymond Bunch - Phoenix AZ, US
Tom Anchordoquy - Lakewood CO, US
Karen E. Stevens - Westminster CO, US
Raymond Bunch - Phoenix AZ, US
Tom Anchordoquy - Lakewood CO, US
Karen E. Stevens - Westminster CO, US
Assignee:
The Regents of the University of Colorado - Denver CO
International Classification:
A61K 31/7076, A61K 31/27, A61K 31/53, A61K 31/195, A61K 31/19, A61K 31/55, A61K 31/551, A61K 31/4178, A61K 31/135, A61P 25/18
US Classification:
514 46, 514483, 514242, 514562, 514557, 514217, 514220, 514397, 514646
Abstract:
The present invention concerns compositions, methods and/or apparatus of central administration of various CNS-active agents. In particular embodiments, intrathecal administration is advantageous for decreasing the systemic concentrations of CNS agent, thereby decreasing side effect toxicity, while allowing more effective delivery of the agent to the site of action, simultaneously decreasing the dosage delivered to the subject. In particular embodiments, ICV delivery may be of use for patients who have previously proven to be refractory to systemic administration of CNS agents, in some cases due to systemic side effects, or for those patients whose symptoms are of sufficient severity to warrant more aggressive therapeutic intervention. ICV administration allows not only lower systemic concentration but also higher therapeutically effective concentration within the CNS.
Central Administration Of Stable Formulations Of Therapeutic Agents For Cns Conditions
US Patent:
2009006, Mar 12, 2009
Filed:
Jul 25, 2008
Appl. No.:
12/180373
Inventors:
Daniel J. Abrams - Denver CO, US
Raymond Bunch - Phoenix AZ, US
Tom Anchordoquy - Lakewood CO, US
Karen E. Stevens - Westminster CO, US
Raymond Bunch - Phoenix AZ, US
Tom Anchordoquy - Lakewood CO, US
Karen E. Stevens - Westminster CO, US
International Classification:
A61K 31/7076, A61K 31/551, A61K 31/519, A61K 31/137, A61K 31/55, A61P 25/28
US Classification:
514 46, 514220, 51425941, 514651, 514217, 51421113
Abstract:
The present invention concerns compositions, methods and/or apparatus of central administration of various CNS-active agents. In particular embodiments, intrathecal administration is advantageous for decreasing the systemic concentrations of CNS agent, thereby decreasing side effect toxicity, while allowing more effective delivery of the agent to the site of action, simultaneously decreasing the dosage delivered to the subject. In particular embodiments, ICV delivery may be of use for patients who have previously proven to be refractory to systemic administration of CNS agents, in some cases due to systemic side effects, or for those patients whose symptoms are of sufficient severity to warrant more aggressive therapeutic intervention. ICV administration allows not only lower systemic concentration but also higher therapeutically effective concentration within the CNS.
Karen Stevens, Thornton CO - LCSW
Specialties:
Social Work, Clinical Social Work
Address:
9101 Pearl St SUITE 218, Thornton 80229
(303) 280-0234 (Fax)
(303) 280-0234 (Fax)
Languages:
English